NCT01826422View on ClinicalTrials.gov

Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Muscular Dystrophy, Duchenne
Interventions
DIETARY_SUPPLEMENT

EPA and DHA

Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.

DIETARY_SUPPLEMENT

Placebo Comparator

Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.

Trial Locations (1)

06720

Unit of Medical Researcha in Nutrition, Pediatric Hospital, IMSS., Mexico City

All Listed Sponsors
collaborator

Instituto Nacional de Rehabilitacion

OTHER_GOV

lead

Coordinación de Investigación en Salud, Mexico

OTHER_GOV

NCT01826422 - Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients | Biotech Hunter | Biotech Hunter